The Nonsensical Downgrading of Development-Stage Firms Like Intellia Therapeutics
It makes no sense to downgrade a development-stage firm such as CRiSPR gene editing IntelliaTherapeutics (NTLA) when only based on stopping short of attaining analysts’ expectations with regard to revenues and incomes. Development-stage firms yet to have products on the market to generate money, contrarily, serious development-stage firms . . .
This content is for paid subscribers.
Trick or Trade March 9, 2021